The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies
Open accessAbstract
The COVID-19 pandemic has created significant concern for everyone. Recent data from many worldwide reports suggest that most infections are caused by the Omicron variant and its sub-lineages, dominating all the previously emerged variants. The numerous mutations in Omicron’s viral genome and its sub-lineages attribute it a larger amount of viral fitness, owing to the alteration of the transmission and pathophysiology of the virus. With a rapid change to the viral structure, Omicron and its sub-variants, namely BA.1, BA.2, BA.3, BA.4, and BA.5, dominate the community with an ability to escape the neutralization efficiency induced by prior vaccination or infections. Similarly, several recombinant sub-variants of Omicron, namely XBB, XBD, and XBF, etc., have emerged, which a better understanding. This review mainly entails the changes to Omicron and its sub-lineages due to it having a higher number of mutations. The binding affinity, cellular entry, disease severity, infection rates, and most importantly, the immune evading potential of them are discussed in this review. A comparative analysis of the Delta variant and the other dominating variants that evolved before Omicron gives the readers an in-depth understanding of the landscape of Omicron’s transmission and infection. Furthermore, this review discusses the range of neutralization abilities possessed by several approved antiviral therapeutic molecules and neutralizing antibodies which are functional against Omicron and its sub-variants. The rapid evolution of the sub-variants is causing infections, but the broader aspect of their transmission and neutralization has not been explored. Thus, the scientific community should adopt an elucidative approach to obtain a clear idea about the recently emerged sub-variants, including the recombinant variants, so that effective neutralization with vaccines and drugs can be achieved. This, in turn, will lead to a drop in the number of cases and, finally, an end to the pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,335
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
Karim, S. S. A., & Karim, Q. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02758-6 · Cited by 1,226
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04474-x · Cited by 1,146
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., De Marco, A., di Iulio, J., et al. (2022) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,080
Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00017-4 · Cited by 1,041
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., Marco, A. D., Lempp, F., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · doi:10.1101/2021.01.14.426475 · Cited by 901
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889
Araf, Y., Akter, F., Tang, Y., Fatemi, R., Parvez, M. S. A., Zheng, C., & Hossain, M. G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27588 · Cited by 862
Menni, C., Valdes, A. M., Polidori, L., Antonelli, M., Penamakuri, S., Nogal, A., Louca, P., May, A., Figueiredo, J. C., Hu, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00327-0 · Cited by 854
SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
Hui, K. P. Y., Ho, J. C. W., Cheung, M.-C., Ng, K.-C., Ching, R. H. H., Lai, K.-L., Kam, T. T., Gu, H., Sit, K.-Y., Hsin, M. K. Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04479-6 · Cited by 836
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01143-7 · Cited by 785
The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets
Peacock, T. P., Goldhill, D. H., Zhou, J., Baillon, L., Frise, R., Swann, O. C., Kugathasan, R., Penn, R., Brown, J. C., Sanchez-David, R. Y., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00908-w · Cited by 731
Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., Panda, S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9071542 · Cited by 730
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., Subramoney, K., Makatini, Z., Moyo, S., Amoako, D. G., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01911-2 · Cited by 707
Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., & Wu, J. T. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.26.1.2002106 · Cited by 694
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Halfmann, P. J., Iida, S., Iwatsuki-Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S., Singh, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04441-6 · Cited by 694
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., Duyvesteyn, H. M. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.005 · Cited by 686
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Suzuki, R., Yamasoba, D., Kimura, I., Wang, L., Kishimoto, M., Ito, J., Morioka, Y., Nao, N., Nasser, H., Uriu, K., et al. (2022) · Nature · doi:10.1038/s41586-022-04462-1 · Cited by 682
Izcovich, A., Ragusa, M. A., Tortosa, F., Lavena Marzio, M. A., Agnoletti, C., Bengolea, A., Ceirano, A., Espinosa, F., Saavedra, E., Sanguine, V., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241955 · Cited by 660
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
Shuai, H., Chan, J. F.-W., Hu, B., Chai, Y., Yuen, T. T.-T., Yin, F., Huang, X., Yoon, C., Hu, J.-C., Liu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04442-5 · Cited by 654
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K. S., Marquez, A. C., Sekirov, I., & Subramaniam, S. (2022) · Science · doi:10.1126/science.abn7760 · Cited by 630
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208343 · Cited by 627
SARS-CoV-2 Omicron variant: recent progress and future perspectives
Fan, Y., Li, X., Zhang, L., Wan, S., Zhang, L., & Zhou, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00997-x · Cited by 589
Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein
Kumar, S., Thambiraja, T. S., Karuppanan, K., & Subramaniam, G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27526 · Cited by 579
Heavily mutated Omicron variant puts scientists on alert
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-03552-w · Cited by 553
Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519
SARS‐CoV‐2 Omicron variant: Characteristics and prevention
He, X., Hong, W., Pan, X., Lu, G., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.110 · Cited by 506
Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
Han, P., Li, L., Liu, S., Wang, Q., Zhang, D., Xu, Z., Han, P., Li, X., Peng, Q., Su, C., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.001 · Cited by 490
Iuliano, A. D., Brunkard, J. M., Boehmer, T. K., Peterson, E., Adjei, S., Binder, A. M., Cobb, S., Graff, P., Hidalgo, P., Panaggio, M. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104e4 · Cited by 442
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., et al. (2021) · doi:10.1101/2021.12.07.21267432 · Cited by 440
Vangeel, L., Chiu, W., De Jonghe, S., Maes, P., Slechten, B., Raymenants, J., André, E., Leyssen, P., Neyts, J., & Jochmans, D. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105252 · Cited by 433
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.019 · Cited by 424
Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R., Lipsitch, M., & Tartof, S. Y. (2022) · Nature Medicine · doi:10.1038/s41591-022-01887-z · Cited by 390
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
Takashita, E., Kinoshita, N., Yamayoshi, S., Sakai-Tagawa, Y., Fujisaki, S., Ito, M., Iwatsuki-Horimoto, K., Chiba, S., Halfmann, P., Nagai, H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119407 · Cited by 376
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Dejnirattisai, W., Zhou, D., Ginn, H. M., Duyvesteyn, H. M. E., Supasa, P., Case, J. B., Zhao, Y., Walter, T. S., Mentzer, A. J., Liu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.032 · Cited by 371
Liu, Y., & Rocklöv, J. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac037 · Cited by 368
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Arbel, R., Wolff Sagy, Y., Hoshen, M., Battat, E., Lavie, G., Sergienko, R., Friger, M., Waxman, J. G., Dagan, N., Balicer, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204919 · Cited by 356
Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021
Brandal, L. T., MacDonald, E., Veneti, L., Ravlo, T., Lange, H., Naseer, U., Feruglio, S., Bragstad, K., Hungnes, O., Ødeskaug, L. E., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.50.2101147 · Cited by 318
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs
Saravolatz, L. D., Depcinski, S., & Sharma, M. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac180 · Cited by 303
Khandia, R., Singhal, S., Alqahtani, T., Kamal, M. A., El-Shall, N. A., Nainu, F., Desingu, P. A., & Dhama, K. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112816 · Cited by 300
Self-citationStructures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody
Yin, W., Xu, Y., Xu, P., Cao, X., Wu, C., Gu, C., He, X., Wang, X., Huang, S., Yuan, Q., et al. (2022) · Science · doi:10.1126/science.abn8863 · Cited by 283
How bad is Omicron? What scientists know so far
Callaway, E., & Ledford, H. (2021) · Nature · doi:10.1038/d41586-021-03614-z · Cited by 277
Wong, C. K. H., Au, I. C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00507-2 · Cited by 269
SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance
Zhang, X., Wu, S., Wu, B., Yang, Q., Chen, A., Li, Y., Zhang, Y., Pan, T., Zhang, H., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00852-5 · Cited by 262
Shah, M., & Woo, H. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.830527 · Cited by 255
Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation
Long, B., Carius, B. M., Chavez, S., Liang, S. Y., Brady, W. J., Koyfman, A., & Gottlieb, M. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.01.028 · Cited by 252
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies
Dhama, K., Nainu, F., Frediansyah, A., Yatoo, M. I., Mohapatra, R. K., Chakraborty, S., Zhou, H., Islam, M. R., Mamada, S. S., Kusuma, H. I., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.11.024 · Cited by 246
Self-citationSimmonds, P. (2020) · mSphere · doi:10.1128/msphere.00408-20 · Cited by 245
Kumar, S., Karuppanan, K., & Subramaniam, G. (2022) · doi:10.1101/2022.02.11.480029 · Cited by 223
Kumar, S., Karuppanan, K., & Subramaniam, G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27927 · Cited by 223
Impact of the delta variant on vaccine efficacy and response strategies
Bian, L., Gao, Q., Gao, F., Wang, Q., He, Q., Wu, X., Mao, Q., Xu, M., & Liang, Z. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1976153 · Cited by 219
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?
Jung, C., Kmiec, D., Koepke, L., Zech, F., Jacob, T., Sparrer, K. M. J., & Kirchhoff, F. (2022) · Journal of Virology · doi:10.1128/jvi.02077-21 · Cited by 213
Christensen, P. A., Olsen, R. J., Long, S. W., Snehal, R., Davis, J. J., Ojeda Saavedra, M., Reppond, K., Shyer, M. N., Cambric, J., Gadd, R., et al. (2022) · The American Journal of Pathology · doi:10.1016/j.ajpath.2022.01.007 · Cited by 212
Wu, L., Zhou, L., Mo, M., Liu, T., Wu, C., Gong, C., Lu, K., Gong, L., Zhu, W., & Xu, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00863-2 · Cited by 210
Syed, A. M., Ciling, A., Taha, T. Y., Chen, I. P., Khalid, M. M., Sreekumar, B., Chen, P.-Y., Kumar, G. R., Suryawanshi, R., Silva, I., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200592119 · Cited by 207
Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses
Nguyen, T. M., Zhang, Y., & Pandolfi, P. P. (2020) · Cell Research · doi:10.1038/s41422-020-0290-0 · Cited by 185
Bouzid, D., Visseaux, B., Kassasseya, C., Daoud, A., Fémy, F., Hermand, C., Truchot, J., Beaune, S., Javaud, N., Peyrony, O., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0308 · Cited by 179
Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function
Yang, T., Yu, P., Chang, Y., Liang, K.-H., Tso, H.-C., Ho, M., Wy, C., Lin, H.-T., Wu, H., & Hsu, S. D. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00652-z · Cited by 169
Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.801522 · Cited by 158
Self-citationWhere did ‘weird’ Omicron come from?
Kupferschmidt, K. (2021) · Science · doi:10.1126/science.acx9738 · Cited by 154
Sheehan, M. M., Reddy, A. J., & Rothberg, M. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab234 · Cited by 142
Emergence of Omicron third lineage BA.3 and its importance
Desingu, P. A., Nagarajan, K., & Dhama, K. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27601 · Cited by 142
Self-citationTada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R. S., Hubbard, S. R., Mulligan, M. J., & Landau, N. R. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103944 · Cited by 134
How severe are Omicron infections?
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-03794-8 · Cited by 127
What Omicron’s BA.4 and BA.5 variants mean for the pandemic
Callaway, E. (2022) · Nature · doi:10.1038/d41586-022-01730-y · Cited by 127
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 125
High Rate of Asymptomatic Carriage Associated with Variant Strain OmicronPreprint
Garrett, N., Tapley, A., Andriesen, J. G., Seocharan, I., Fisher, L. H., Bunts, L., Espy, N., Wallis, C. L., Randhawa, A. K., Ketter, N., et al. (2021) · medRxiv · doi:10.1101/2021.12.20.21268130 · Cited by 125
Bojková, D., Widera, M., Ciesek, S., Wass, M. N., Michaelis, M., & Cinatl, J. (2022) · Cell Research · doi:10.1038/s41422-022-00619-9 · Cited by 123
SARS-CoV-2 reinfection and COVID-19 severity
Nguyen, N. N., Houhamdi, L., Hoang, V. T., Delerce, J., Delorme, L., Colson, P., Brouqui, P., Fournier, P., Raoult, D., & Gautret, P. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2052358 · Cited by 112
Cryo-EM structure of the SARS-CoV-2 Omicron spike
Cerutti, G., Guo, Y., Liu, L., Liu, L., Zhang, Z., Luo, Y., Huang, Y., Wang, H. H., Ho, D. D., Sheng, Z., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110428 · Cited by 109
Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant?
Duong, B. V., Larpruenrudee, P., Fang, T., Hossain, S. I., Saha, S. C., Gu, Y., & Islam, M. S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19084586 · Cited by 108
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern
Akkız, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.849217 · Cited by 103
Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants
da Costa, C. H. S., de Freitas, C. A. B., Alves, C. N., & Lameira, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-12479-9 · Cited by 101
Taylor, C. A., WHITAKER, M. D., Anglin, O., Milucky, J., Patel, K., Pham, H., Chai, S. J., Alden, N. B., Yousey-Hindes, K. M., Anderson, E. J., et al. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7112e2 · Cited by 97
Omicron adopts a different strategy from Delta and other variants to adapt to host
Du, X., Tang, H., Gao, L., Wu, Z., Meng, F., Yan, R., Qiao, S., An, J., Wang, C., & Qin, F. X.-F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00903-5 · Cited by 94
Riediker, M., Briceño-Ayala, L., Ichihara, G., Albani, D., Poffet, D., Tsai, D.-H., Iff, S., & Monn, C. (2022) · Swiss Medical Weekly · doi:10.4414/smw.2022.w30133 · Cited by 93
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates
Mohapatra, R. K., Tiwari, R., Sarangi, A. K., Islam, M. R., Chakraborty, C., & Dhama, K. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27633 · Cited by 84
Self-citationFeikin, D. R., Abu-Raddad, L. J., Andrews, N., Davies, M.-A., Higdon, M. M., Orenstein, W. A., & Patel, M. K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.069 · Cited by 83
Chaguza, C., Coppi, A. C., Earnest, R., Ferguson, D. J. P., Kerantzas, N., Warner, F. J., Young, H. P., Breban, M. I., Billig, K., Koch, R. T., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.010 · Cited by 83
Chen, X., Yan, X., Sun, K., Zheng, N., Sun, R., Zhou, J., Deng, X., Zhuang, T., Cai, J., Zhang, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2128435 · Cited by 81
Zhou, H., Møhlenberg, M., Thakor, J. C., Tuli, H. S., Wang, P., Assaraf, Y. G., Dhama, K., & Jiang, S. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-22 · Cited by 78
Self-citationChakraborty, C., Bhattacharya, M., Sharma, A. R., & Mallik, B. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.254 · Cited by 75
Self-citationConvulsions in children with COVID‐19 during the Omicron wave
Ludvigsson, J. F. (2022) · Acta Paediatrica · doi:10.1111/apa.16276 · Cited by 74
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
Zhang, L., Cao, L., Gao, X., Zheng, B., Deng, Y., Li, J., Feng, R., Bian, Q., Guo, X., Wang, N., et al. (2021) · National Science Review · doi:10.1093/nsr/nwab053 · Cited by 72
Clinical Characteristics of COVID-19 Patients Infected by the Omicron Variant of SARS-CoV-2
Zhang, J., Chen, N., Zhao, D., Zhang, J., Hu, Z., & Tao, Z. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.912367 · Cited by 72
Brüssow, H. (2022) · Microbial Biotechnology · doi:10.1111/1751-7915.14064 · Cited by 71
Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
Kared, H., Wolf, A., Alirezaylavasani, A., Ravussin, A., Solum, G., Tran, T. T., Lund‐Johansen, F., Vaage, J. T., Nissen‐Meyer, L. S. H., Nygaard, U. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31888-y · Cited by 70
Bhattacharya, M., Sharma, A. R., Dhama, K., Agoramoorthy, G., & Chakraborty, C. (2022) · GeroScience · doi:10.1007/s11357-022-00532-4 · Cited by 69
Self-citationThe omicron variant of SARS‐CoV‐2: Understanding the known and living with unknowns
Ingraham, N. E., & Ingbar, D. H. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.685 · Cited by 68
Islam, F., Dhawan, M. K., Nafady, M. H., Emran, T. B., Mitra, S., Choudhary, O. P., & Akter, A. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103737 · Cited by 55
Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective
Mohapatra, R. K., Kandi, V., Verma, S., & Dhama, K. (2022) · ChemBioChem · doi:10.1002/cbic.202200059 · Cited by 53
Self-citationBhattacharya, M., Chatterjee, S., Sharma, A. R., Lee, S., & Chakraborty, C. (2022) · Folia Microbiologica · doi:10.1007/s12223-022-01001-3 · Cited by 52
Self-citationThe Mutation Profile of SARS-CoV-2 Is Primarily Shaped by the Host Antiviral Defense
Azgari, C., Kilinç, Z., Turhan, B., Çırcı, D., & Adebalı, O. (2021) · Viruses · doi:10.3390/v13030394 · Cited by 50
Chakraborty, C., Bhattacharya, M., & Sharma, A. R. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.006 · Cited by 45
Self-citationIncidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
Wong, G. L., Yip, T. C., Lai, M. S., Wong, V. W., Hui, D. S. C., & Lui, G. C.-Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45086 · Cited by 39
Sun, C., Kang, Y., Liu, Y.-T., Kong, X., Xu, H.-Q., Xiong, D., Xie, C., Liu, Y., Peng, S., Feng, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00910-6 · Cited by 38
Influence of immune escape and nasopharyngeal virus load on the spread of SARS-CoV-2 Omicron variant
Migueres, M., Dimeglio, C., Trémeaux, P., Abravanel, F., Raymond, S., Lhomme, S., Mansuy, J., & Izopet, J. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.01.036 · Cited by 37
A Unique SARS-CoV-2 Spike Protein P681H Variant Detected in Israel
Zuckerman, N. S., Fleishon, S., Bucris, E. D., Bar-Ilan, D., Linial, M., Bar-Or, I., Indenbaum, V., Weil, M., Lustig, Y., Mendelson, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9060616 · Cited by 34
A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
Zhou, B., Zhou, R., Tang, B., Chan, J. F., Luo, M., Peng, Q., Yuan, S., Liu, H., Mok, B. W.-Y., Chen, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31259-7 · Cited by 32
Fang, Z., Monteiro, V. S., Hahn, A. M., Grubaugh, N. D., Lucas, C. G. D. O., & Chen, S. (2022) · Cell Discovery · doi:10.1038/s41421-022-00473-4 · Cited by 32
Rahman, S., Hossain, M. J., Nahar, Z., Shahriar, M., Bhuiyan, M. A., & Islam, M. R. (2022) · Environmental Health Insights · doi:10.1177/11786302221129396 · Cited by 29
Pilz, S., & Ioannidis, J. P. A. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13906 · Cited by 29
Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update
Bhattacharya, M., Chatterjee, S., Lee, S., & Chakraborty, C. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.284 · Cited by 29
Self-citationKneidinger, N., Hecker, M., Bessa, V., Hettich, I. M., Wald, A., Wege, S., Nolde, A., Oldigs, M., Syunyaeva, Z., Wilkens, H., et al. (2022) · Infection · doi:10.1007/s15010-022-01914-8 · Cited by 28
Chakraborty, C., Bhattacharya, M., Sharma, A. R., Dhama, K., & Lee, S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.10.004 · Cited by 27
Self-citationOmicron variant infection and the associated immunological scenario
Mukherjee, A. G., Wanjari, U. R., Murali, R., Chaudhary, U., Renu, K., Madhyastha, H., Iyer, M., Vellingiri, B., & Gopalakrishnan, A. V. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152222 · Cited by 22
Coronavirus in Continuous Flux: From SARS‐CoV to SARS‐CoV‐2
Dong, Y., Dai, T., Liu, J., Zhang, L., & Zhou, F. (2020) · Advanced Science · doi:10.1002/advs.202001474 · Cited by 20
Chakraborty, C., Bhattacharya, M., Sharma, A. R., Dhama, K., & Agoramoorthy, G. (2022) · GeroScience · doi:10.1007/s11357-022-00631-2 · Cited by 20
Self-citationBhattacharya, M., Sharma, A. R., Dhama, K., Agoramoorthy, G., & Chakraborty, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108766 · Cited by 17
Self-citationBhattacharya, M., Chatterjee, S., Mallik, B., Sharma, A. R., & Chakraborty, C. (2022) · Vaccines · doi:10.3390/vaccines10101612 · Cited by 17
Self-citationOmicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador
Carrazco-Montalvo, A., Herrera-Yela, A., Alarcón-Vallejo, D., Gutiérrez-Pallo, D., Armendáriz‐Castillo, I., Andrade-Molina, D., Muñoz-Mawyin, K., Fernández‐Cadena, J. C., Gabriel Morey-León, G., Cárdenas, P., et al. (2022) · Viruses · doi:10.3390/v14061177 · Cited by 16
Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., & Lee, S. (2022) · Aging and Disease · doi:10.14336/ad.2021.1117 · Cited by 14
Self-citationPeter, A. S., Grüner, E., Socher, E., Fraedrich, K., Richel, E., Mueller-Schmucker, S. M., Cordsmeier, A., Ensser, A., Sticht, H., & Überla, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158177 · Cited by 13
Chakraborty, C., Bhattacharya, M., Sharma, A. R., Mohapatra, R. K., Chakraborty, S., Pal, S., & Dhama, K. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106903 · Cited by 12
Self-citationChakraborty, C., Sharma, A. R., Bhattacharya, M., Mallik, B., Nandi, S. S., & Lee, S. (2022) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2022.105282 · Cited by 10
Self-citationOmicron variant receptor-binding domain phylogenetics and molecular dynamics
Kandeel, M. K., & El‐Deeb, W. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105633 · Cited by 8
Callebaut, K., Stoefs, A., Stylemans, D., Soetens, O., Crombé, F., Vancutsem, E., Imamura, H., Wybo, I., Geyter, D. D., Piérard, D., et al. (2022) · Viruses · doi:10.3390/v14091852 · Cited by 3
Metadata
- Authors
- Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., & Chakraborty, C.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2023-01-05
- Volume
- 15
- Issue
- 1
- Pages
- 167
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W4313647364
- Cited by
- 313
- References
- 129
- FWCI
- 58.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.